HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Matrixx Bought By Private Equity Firm H.I.G., Settles Personal Injury Lawsuits

This article was originally published in The Tan Sheet

Executive Summary

Matrixx Initiatives announced Dec. 14 private equity firm H.I.G. Capital will acquire the Scottsdale, Ariz.-based maker of Zicam cough/cold products for approximately $75.2 million.

You may also be interested in...



Zicam Maker Matrixx Settles With Shareholders Over H.I.G. Buyout

Matrixx Initiatives remains mired in multiple lawsuits despite settling litigation with shareholders over the firm’s handling of its 2010 buyout.

FDA Warns Matrixx On Combination Supplement/Drug Products

Matrixx Initiatives’ troubled history with FDA continues with a warning two of its products are unapproved new drugs because they combine supplements with OTC drugs.

Matrixx Sales Drop Nearly 30% In Final Quarter Before Buyout

Matrixx Initiatives posts an $11.3 million net loss in what is likely its last quarter as a publicly traded company before its acquisition by private equity firm H.I.G. Capital.

Related Content

Topics

UsernamePublicRestriction

Register

RS135347

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel